Hematology

Joseph Mikhael, MD, has spent decades advancing the treatment of multiple myeloma, and he’s been witness to a remarkable shift in outcomes among older adults.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

Population data reveal serious infections drive CLL hospital costs, clarifying morbidity and mortality in the hematologic cancer and its true economic consequences.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

The findings bolster the case for using Bruton tyrosine kinase inhibitors in the treatment of Richter syndrome.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Early treatment for acute promyelocytic leukemia likely improves mother-baby outcomes, with treatment timing guiding safer delivery.

Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Teclistamab had received an accelerated approval in October 2022; the combination regimen is administered subcutaneously.